Category Archives: Novartis Case

Defending India’s patent law

Source: The Hindu 12 May 2014 No one can attack India’s well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Patent Injunction, US pressure on India | Leave a comment

A flimsy case against Indian pharma

Source: Business Line 10 March 2014 Trade tensions between the US and India are on the rise. Multiple trade organisations have asked the US Trade Representative to designate India a Priority Foreign Country in its annual review of countries that … Continue reading

Posted in access to medicines, Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS, TRIPS flexibilities, US pressure on India | Leave a comment

How drug companies price patients out of survival

Source: Salon As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another health care battle rages in village clinics and corporate boardrooms. Behind the seductive commercials for breakthrough treatments, multinational brands … Continue reading

Posted in access to medicines, Compulsory Licensing, data exclusivity, EU-India FTA, FTAs, Generic drug, Government Use License, HIV/Aids, Indian Patent Law, IP Rights, IPR Enforcement, Medicine Patent Pool, NAFTA, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TB, Trans-Pacific Partnership Agreement, TRIPS, TRIPS flexibilities, WHO, WTO | Tagged , | Leave a comment

SURPRISE! BIG PHARMA DON’T WANT DEVELOPING COUNTRIES HAVING ACCESS TO CHEAP MEDICINE

Source: http://www.vice.com Compared to a number of other nations, India has done an incredible job of keeping medicine cheap enough that its citizens can afford to buy whatever it is that they need. Most importantly, it avoids handing out patents … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS flexibilities | Leave a comment

“Novartis and the Battle to Access Essential Drugs”

Source: Newsclick This feature examines why India’s patenting regime, despite being pro-public in terms of promoting easier access to drugs, has faced considerable criticism, particularly post the Supreme Court decision in the Novartis case. The feature examines why India has … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Novartis Case, patent, patent evergreening, Patent examination system, Sec 3 (d), TRIPS, WTO | Leave a comment

Lawyers Collective Response to Testimony of Mr. Roy F Waldron, Pfizer Inc.

Source: Lawyers Collective Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, IP Rights, Novartis Case, patent, Patent examination system, Right to Health, Sec 3 (d) | Tagged , , | Leave a comment

IPA response to Pfizer’s letter

IPA’s response to Pfizer letter of 23 May 2013 and Testimony before the Subcommittee on Commerce, Manufacturing and Trade of the House Committee of Energy and Commerce on 27 June 2013. Acces the letter here

Posted in access to medicines, Generic drug, IP Rights, IPR Enforcement, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TRIPS, WTO | Leave a comment